Mars Science Laboratory devours budgets
A further budget overrun for NASA's Mars Science Laboratory rover (pictured), due to launch in 2011, could for the first time delay other missions in the agency's cashstrapped planetary-science division.
In a report due to be handed to Congress by the end of July, NASA will announce that the mission needs between $15 million and $115 million more than its estimated price tag -which, at $2.28 billion, is already 40% above an official $1.63-billion estimate made in 2006.
The agency has so far raided technology-development funds within the Mars programme, but if additional costs rise too much, it may have to delay two planned Moon missions. "The time for some tough decisions is here," said NASA science chief Ed Weiler, breaking the news to planetary scientists at an advisory-committee meeting on 9 July at NASA headquarters in Washington DC. Weiler also confirmed, as expected, that NASA would work in partnership with the European Space Agency on all future major Mars missions. 
Europe attacks tactics that delay generic drugs
The European Commission last week promised tougher scrutiny of drug industry deals that maximize profits on branded medicines by slowing consumers' access to cheap generic drugs.
It opened an investigation into Servier, a pharmaceutical company headquartered in Neuilly-sur-Seine, France, and several other drug manufacturers, over agreements that may have breached anti-trust laws.
Neelie Kroes, the European competition commissioner, also announced the final report of her department's 18-month inquiry into competition in the pharmaceutical sector (see http:// tinyurl.com/EUreport). The report says that 'company practices' are delaying the market entry of generic drugs, but notes that shortcomings in Europe's regulatory framework might be a factor too.
An industry trade body, the European Federation of Pharmaceutical Industries and Associations, approved of the reference to regulatory obstacles. It says that the findings show a "welcome shift away from the emotive language" of an interim report released last November.
US renewable energy gets cash boost
The Obama administration announced plans on 9 July to pump billions of dollars directly into the US renewable-energy market, providing a new avenue for funding that had dried up during the banking crisis.
The programme allows developers to receive cash payments, in lieu of existing tax subsidies, for wind, solar and other renewable-energy projects. Until now, such payments had tended to flow through banks, which provided upfront financing in exchange for tax credits. The new approach, sought by the renewable-energy industry and backed by Congress in its February stimulus bill, allows direct access to the subsidies.
The Department of Energy plans to begin accepting applications in August , and estimates that demand could exceed $3 billion, enabling some $10 billion to $14 billion in projects. Leptin, who works on cell shapes and immunity at the University of Cologne, Germany, says that she hopes EMBO will improve connections with India, China and the United States, and that it can influence governments on policy matters such as stem-cell research.
Obama names next head of US Geological Survey
She will move to EMBO's base at the European Molecular Biology Laboratory in Heidelberg, Germany, in January next year. 
